SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: StockDung10/31/2008 1:14:45 PM
   of 5582
 
"Also earlier this month, Mario Gabelli, CEO of New York-based GAMCO Investors, disclosed in a filing that three investment funds he controls have a 5 percent stake in Matrixx."

Feds to take over Gabelli fraud suit.(Mario Gabelli)(Brief article)
Daily Variety, March, 2006 by Goldsmith, Jill

The Justice Department said Wednesday it will pursue civil fraud claims against Mario Gabelli, the iconic fund manager who's been among the most influential media and entertainment investors of the past two decades. A DOJ lawyer said the government would take over a private lawsuit alleging that Gabelli schemed to deceive the FCC in auctions of cellphone spectrum. findarticles.com
----------------------------------------------------

Matrixx CEO to retire; search is under way for replacement
by Ken Alltucker - Oct. 23, 2008 12:00 AM
The Arizona Republic

Matrixx Initiatives said that Chief Executive Officer Carl Johnson will retire at the end of this month.

Chief Financial Officer William Hemelt will take on the additional roles of acting president and chief operating officer and will be responsible for day-to-day management of the Phoenix-based seller of over-the-counter cold and cough products. The company will search for a new CEO.

A company-issued news release credited Johnson, who joined Matrixx in 2001, with helping sustain the company's profit and revenue growth as well as making Zicam one of the top-selling cold and cough medicines. Johnson also managed the company as it fended off dozens of lawsuits that claimed a link between a Zicam gel product and a condition that led to the loss of taste and smell.

Johnson's retirement was announced as Matrixx reported that its fiscal second-quarter profits jumped 29 percent and revenue increased 18 percent.

Matrixx reported net income of $8.2 million, or 86 cents per diluted share, on revenue of $33.6 million for the three months that ended Sept. 30. That compared to net income of $6.4 million, or 63 cents per diluted share, on revenue of $28.6 million for the same quarter one year ago.

Also earlier this month, Mario Gabelli, CEO of New York-based GAMCO Investors, disclosed in a filing that three investment funds he controls have a 5 percent stake in Matrixx.

His filings did not elaborate whether he intends to take an activist role in Matrixx as he has with his other investments, such as Cablevision and Media General.

Matrixx shares closed Wednesday at $17.53, up 28 cents.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext